

Susan L Davis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1207449/publications.pdf>

Version: 2024-02-01

104
papers

2,999
citations

159585

30
h-index

168389

53
g-index

105
all docs

105
docs citations

105
times ranked

3294
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of the selection of cerebrospinal fluid testing in suspected meningitis and encephalitis. <i>Diagnostic Microbiology and Infectious Disease</i> , 2022, 102, 115571.	1.8	4
2	The long-term sustainability of a respiratory culture nudge. <i>Antimicrobial Stewardship & Healthcare Epidemiology</i> , 2022, 2, .	0.5	3
3	Transitions of care: An untapped opportunity for antimicrobial stewardship. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2022, 5, 632-643.	1.0	1
4	Multicenter Cohort Study of Ceftaroline Versus Daptomycin for Treatment of Methicillin-Resistant <i>Staphylococcus aureus</i> Bloodstream Infection. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab606.	0.9	12
5	Pharmacist-Driven Transitions of Care Practice Model for Prescribing Oral Antimicrobials at Hospital Discharge. <i>JAMA Network Open</i> , 2022, 5, e2211331.	5.9	15
6	High-Dose Daptomycin Is Well Tolerated via 2-Minute IV Push Administration. <i>Hospital Pharmacy</i> , 2021, 56, 328-331.	1.0	2
7	Economic and social drivers of antibiotic dispensing practices among community pharmacies in Nepal. <i>Tropical Medicine and International Health</i> , 2021, 26, 557-571.	2.3	5
8	Real-world, Multicenter Experience With Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant <i>Enterobacterales</i> and <i>Pseudomonas aeruginosa</i> . <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab371.	0.9	36
9	Outcomes of clinical decision support for outpatient management of <i>Clostridioides difficile</i> infection. <i>Infection Control and Hospital Epidemiology</i> , 2021, , 1-4.	1.8	0
10	Antimicrobial never events: Objective application of a framework to assess vancomycin appropriateness. <i>Infection Control and Hospital Epidemiology</i> , 2021, 42, 1121-1123.	1.8	1
11	Impact of Reported β -Lactam Allergy on Management of Methicillin-Sensitive <i>Staphylococcus aureus</i> Bloodstream Infections. <i>Journal of Pharmacy Practice</i> , 2020, 33, 809-814.	1.0	5
12	Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant <i>Pseudomonas aeruginosa</i> . <i>Clinical Infectious Diseases</i> , 2020, 71, 304-310.	5.8	126
13	Daptomycin Plus β -Lactam Combination Therapy for Methicillin-resistant <i>Staphylococcus aureus</i> Bloodstream Infections: A Retrospective, Comparative Cohort Study. <i>Clinical Infectious Diseases</i> , 2020, 71, 1-10.	5.8	79
14	Discharge Delays and Costs Associated With Outpatient Parenteral Antimicrobial Therapy for High-Priced Antibiotics. <i>Clinical Infectious Diseases</i> , 2020, 71, e88-e93.	5.8	14
15	Impact of unit-specific metrics and prescribing tools on a family medicine ward. <i>Infection Control and Hospital Epidemiology</i> , 2020, 41, 1272-1278.	1.8	0
16	Outpatient <i>Clostridioides difficile</i> infections: An opportunity for antimicrobial stewardship programs. <i>Infection Control and Hospital Epidemiology</i> , 2020, 41, 969-971.	1.8	1
17	Antimicrobial Stewardship Metrics that Matter. <i>Infectious Diseases in Clinical Practice</i> , 2020, 28, 89-93.	0.3	2
18	Real-world Multicenter Analysis of Clinical Outcomes and Safety of Meropenem-Vaborbactam in Patients Treated for Serious Gram-Negative Bacterial Infections. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa051.	0.9	36

#	ARTICLE	IF	CITATIONS
19	Evaluation of the INCREMENT-CPE, Pitt Bacteremia and qPitt Scores in Patients with Carbapenem-Resistant Enterobacteriaceae Infections Treated with Ceftazidime-â€“Avibactam. <i>Infectious Diseases and Therapy</i> , 2020, 9, 291-304.	4.0	12
20	Early Experience With Eravacycline for Complicated Infections. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa071.	0.9	27
21	A Multicenter Evaluation of Vancomycin-Associated Acute Kidney Injury in Hospitalized Patients with Acute Bacterial Skin and Skin Structure Infections. <i>Infectious Diseases and Therapy</i> , 2020, 9, 89-106.	4.0	24
22	Treatment and outcomes of <i>Enterococcus faecium</i> bloodstream infections in solid organ transplant recipients. <i>Transplant Infectious Disease</i> , 2020, 22, e13251.	1.7	5
23	Recommended Revisions to the National SEPâ€“1 Sepsis Quality Measure: A commentary by the Society of Infectious Diseases Pharmacists on the Infectious Diseases Society of America Position Paper. <i>Pharmacotherapy</i> , 2020, 40, 368-371.	2.6	1
24	Opportunities for antimicrobial stewardship among carbapenem-treated patients in 18 North American hospitals. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105970.	2.5	7
25	Real-World Experience with Ceftolozane-Tazobactam for Multidrug-Resistant Gram-Negative Bacterial Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	43
26	T2 Candida versus beta-D-glucan to facilitate antifungal discontinuation in the intensive care unit. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 95, 162-165.	1.8	16
27	Comparison of Neutropenia Associated with Ceftaroline or Ceftriaxone in Patients Receiving at Least 7 Days of Therapy for Severe Infections. <i>Pharmacotherapy</i> , 2019, 39, 809-815.	2.6	5
28	Improving care for critically ill patients with community-acquired pneumonia. <i>American Journal of Health-System Pharmacy</i> , 2019, 76, 861-868.	1.0	6
29	Trends in and Predictors of Carbapenem Consumption across North American Hospitals: Results from a Multicenter Survey by the MAD-ID Research Network. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	10
30	Open-Label Randomized Trial of Early Clinical Outcomes of Ceftaroline Fosamil Versus Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections at Risk of Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>Infectious Diseases and Therapy</i> , 2019, 8, 199-208.	4.0	7
31	Diagnostic Stewardship: A Clinical Decision Rule for Blood Cultures in Community-Onset Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA) Skin and Soft Tissue Infections. <i>Infectious Diseases and Therapy</i> , 2019, 8, 229-242.	4.0	7
32	182. Appropriateness of Treatment Duration for <i>S. aureus</i> Bacteremia (SAB). <i>Open Forum Infectious Diseases</i> , 2019, 6, S112-S112.	0.9	0
33	1989. Impact of Pharmacist-Led Î²-Lactam Allergy Clarification Interview on Optimizing Preoperative Antibiotic Prophylaxis. <i>Open Forum Infectious Diseases</i> , 2019, 6, S667-S667.	0.9	0
34	2000. Utilization of a â€“Never Eventâ€“™ Framework to Classify Antimicrobial Appropriateness. <i>Open Forum Infectious Diseases</i> , 2019, 6, S670-S671.	0.9	0
35	759. High-Dose Daptomycin Is Well Tolerated via 2-Minute Infusion. <i>Open Forum Infectious Diseases</i> , 2019, 6, S338-S339.	0.9	1
36	772. Access Denied: Impact of Insurance Denials for High-Cost Outpatient Parenteral Antimicrobial Therapy. <i>Open Forum Infectious Diseases</i> , 2019, 6, S343-S343.	0.9	0

#	ARTICLE	IF	CITATIONS
37	2254. Multicenter Evaluation of Ceftazidime-â€“Avibactam for Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Infections. <i>Open Forum Infectious Diseases</i> , 2019, 6, S771-S772.	0.9	0
38	Real-World Experience With Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz522.	0.9	85
39	Risk Factors for Bloodstream Infections Among an Urban Population with Skin and Soft Tissue Infections: A Retrospective Unmatched Case-Control Study. <i>Infectious Diseases and Therapy</i> , 2019, 8, 75-85.	4.0	2
40	It is time to define antimicrobial never events. <i>Infection Control and Hospital Epidemiology</i> , 2019, 40, 206-207.	1.8	9
41	Multicenter Assessment of Antibiotic Prophylaxis Spectrum on Surgical Infections in Head and Neck Cancer Microvascular Reconstruction. <i>Otolaryngology - Head and Neck Surgery</i> , 2018, 159, 59-67.	1.9	19
42	Ambulatory Quinolone Prescribing: Moving From Opportunity to Implementation. <i>Clinical Infectious Diseases</i> , 2018, 67, 1306-1307.	5.8	4
43	Stewardship opportunities in viral pneumonia: Why not the immunocompromised?. <i>Transplant Infectious Disease</i> , 2018, 20, e12854.	1.7	15
44	Delafloxacin: Place in Therapy and Review of Microbiologic, Clinical and Pharmacologic Properties. <i>Infectious Diseases and Therapy</i> , 2018, 7, 197-217.	4.0	74
45	Novel application of published risk factors for methicillin-resistant <i>S. aureus</i> in acute bacterial skin and skin structure infections. <i>International Journal of Antimicrobial Agents</i> , 2018, 51, 43-46.	2.5	10
46	Antimicrobial Stewardship Opportunities in Critically Ill Patients with Gram-Negative Lower Respiratory Tract Infections: A Multicenter Cross-Sectional Analysis. <i>Infectious Diseases and Therapy</i> , 2018, 7, 135-146.	4.0	14
47	2043. T2- <i>Candida</i> (T2MR) vs. β -D-Glucan (BDG) for Preemptive Antifungal Stewardship in the Intensive Care Unit (ICU). <i>Open Forum Infectious Diseases</i> , 2018, 5, S596-S596.	0.9	0
48	2406. â€œReal-worldâ€•Treatment of Multidrug-Resistant (MDR) or Extensively Drug-Resistant (XDR) <i>P. aeruginosa</i> Infections With Ceftolozane/Tazobactam (C/T) vs. a Polymyxin or Aminoglycoside (Poly/AG)-based Regimen: A Multicenter Comparative Effectiveness Study. <i>Open Forum Infectious Diseases</i> , 2018, 5, S719-S719.	0.9	1
49	1884. Assessment of Potential Antimicrobial-Related Harms in Hospitalized Adults With Common Infections. <i>Open Forum Infectious Diseases</i> , 2018, 5, S539-S539.	0.9	1
50	2379. Multicenter Evaluation of Ceftazidime-â€“Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections. <i>Open Forum Infectious Diseases</i> , 2018, 5, S708-S709.	0.9	0
51	192. More Low-hanging Fruit: Antibiotic Chelation Drug Interactions. <i>Open Forum Infectious Diseases</i> , 2018, 5, S84-S85.	0.9	0
52	2366. Treatment Characteristics and Predictors of Mortality in Patients With Infected Chronic Pressure Ulcers in Detroit. <i>Open Forum Infectious Diseases</i> , 2018, 5, S704-S704.	0.9	0
53	2384. Multidrug-Resistant Gram-Negative Infections Treated With Ceftolozane-â€“Tazobactam: Impact of Delayed Initiation. <i>Open Forum Infectious Diseases</i> , 2018, 5, S710-S711.	0.9	0
54	238. Sharing Unit-Specific Stewardship Metrics With Front-line Providers to Improve Antibiotic Prescribing. <i>Open Forum Infectious Diseases</i> , 2018, 5, S102-S102.	0.9	0

#	ARTICLE	IF	CITATIONS
55	Development of a Risk-Scoring Tool to Determine Appropriate Level of Care in Acute Bacterial Skin and Skin Structure Infections in an Acute Healthcare Setting. <i>Infectious Diseases and Therapy</i> , 2018, 7, 495-507.	4.0	2
56	Microbiology Comment Nudge Improves Pneumonia Prescribing. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy162.	0.9	51
57	Combatting resistant enterococcal infections: a pharmacotherapy review. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 979-992.	1.8	62
58	Creating objective and measurable postgraduate year 1 residency graduation requirements. <i>American Journal of Health-System Pharmacy</i> , 2017, 74, 389-396.	1.0	3
59	Multicenter Observational Study of Ceftaroline Fosamil for Methicillin-Resistant <i>Staphylococcus aureus</i> Bloodstream Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	60
60	Multidrug-resistant <i>Pseudomonas aeruginosa</i> lower respiratory tract infections in the intensive care unit: Prevalence and risk factors. <i>Diagnostic Microbiology and Infectious Disease</i> , 2017, 89, 61-66.	1.8	28
61	The Safety and Economic Impact of Cefazolin versus Nafcillin for the Treatment of Methicillin-Susceptible <i>Staphylococcus aureus</i> Bloodstream Infections. <i>Infectious Diseases and Therapy</i> , 2017, 6, 225-231.	4.0	37
62	Considerations for antibiotic prophylaxis in head and neck cancer surgery. <i>Oral Oncology</i> , 2017, 74, 181-187.	1.5	28
63	Trowels and Tribulations: Review of Antimicrobial-impregnated Bone Cements in Prosthetic Joint Surgery. <i>Pharmacotherapy</i> , 2017, 37, 1565-1577.	2.6	17
64	Impact of Antimicrobial Stewardship Consultation Service at an Academic Institution. <i>Infectious Diseases in Clinical Practice</i> , 2017, 25, 268-271.	0.3	0
65	Randomized Controlled Trial to Determine the Efficacy of Early Switch From Vancomycin to Vancomycin Alternatives as a Strategy to Prevent Nephrotoxicity in Patients With Multiple Risk Factors for Adverse Renal Outcomes (STOP-NT). <i>Annals of Pharmacotherapy</i> , 2017, 51, 185-193.	1.9	22
66	Role of Respiratory Virus Panels in Antimicrobial Stewardship in Immunocompromised Patients. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	2
67	Problems with the current approach to residency research. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 1918-1922.	1.0	1
68	Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum β -lactamase urinary tract infections. <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 56-60.	2.5	43
69	Surgical prophylaxis with gram-negative activity for reduction of surgical site infections after microvascular reconstruction for head and neck cancer. <i>Head and Neck</i> , 2016, 38, 1449-1454.	2.0	14
70	Days of Therapy and Antimicrobial Days: Similarities and Differences Between Consumption Metrics. <i>Infection Control and Hospital Epidemiology</i> , 2016, 37, 971-973.	1.8	3
71	Outpatient use of ceftaroline fosamil versus vancomycin for osteoarticular infection: a matched cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3568-3574.	3.0	8
72	Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant <i>Staphylococcus aureus</i> Bloodstream Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5841-5848.	3.2	58

#	ARTICLE	IF	CITATIONS
73	Reply to "Urinary Tract Infections: Resistance Is Futile", Antimicrobial Agents and Chemotherapy, 2016, 60, 2598-2598.	3.2	0
74	Time Is of the Essence: The Impact of Delayed Antibiotic Therapy on Patient Outcomes in Hospital-Onset Enterococcal Bloodstream Infections. Clinical Infectious Diseases, 2016, 62, 1242-1250.	5.8	99
75	Pneumonia Caused by Methicillin-Resistant Staphylococcus aureus: Does Vancomycin Heteroresistance Matter?. Antimicrobial Agents and Chemotherapy, 2016, 60, 1708-1716.	3.2	35
76	Acute Bacterial Skin and Skin Structure Infections Treated with Intravenous Antibiotics in the Emergency Department or Observational Unit: Experience at the Detroit Medical Center. Infectious Diseases and Therapy, 2015, 4, 173-186.	4.0	19
77	Evaluation of pharmacy generalists performing antimicrobial stewardship services. American Journal of Health-System Pharmacy, 2015, 72, 1298-1303.	1.0	19
78	Association between Vancomycin Day 1 Exposure Profile and Outcomes among Patients with Methicillin-Resistant Staphylococcus aureus Infective Endocarditis. Antimicrobial Agents and Chemotherapy, 2015, 59, 2978-2985.	3.2	68
79	Impact of the Combination of Daptomycin and Trimethoprim-Sulfamethoxazole on Clinical Outcomes in Methicillin-Resistant Staphylococcus aureus Infections. Antimicrobial Agents and Chemotherapy, 2015, 59, 1969-1976.	3.2	29
80	Secular Trends Associated with Enterobacteriaceae with a Cefepime Susceptible-Dose-Dependent MIC. Antimicrobial Agents and Chemotherapy, 2015, 59, 1822-1823.	3.2	2
81	Outcomes of Aminopenicillin Therapy for Vancomycin-Resistant Enterococcal Urinary Tract Infections. Antimicrobial Agents and Chemotherapy, 2015, 59, 7362-7366.	3.2	17
82	Systematic approach to antimicrobial restriction. American Journal of Health-System Pharmacy, 2015, 72, 1264-1265.	1.0	2
83	Impact of Physician Assistant Directed Antimicrobial Stewardship Consultation Service. Open Forum Infectious Diseases, 2014, 1, S99-S99.	0.9	0
84	Crossover Study of Silver-Embedded White Coats in Clinical Practice. Infectious Diseases in Clinical Practice, 2014, 22, 145-147.	0.3	2
85	Large Retrospective Evaluation of the Effectiveness and Safety of Ceftaroline Fosamil Therapy. Antimicrobial Agents and Chemotherapy, 2014, 58, 2541-2546.	3.2	97
86	Evaluation of Vancomycin Population Susceptibility Analysis Profile as a Predictor of Outcomes for Patients with Infective Endocarditis Due to Methicillin-Resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2014, 58, 4636-4641.	3.2	14
87	Impact of a Multidisciplinary Culture Follow-up Program of Antimicrobial Therapy in the Emergency Department. Infectious Diseases and Therapy, 2014, 3, 45-53.	4.0	60
88	Adherence to the 2009 Consensus Guidelines for Vancomycin Dosing and Monitoring Practices: A Cross-Sectional Survey of U.S. Hospitals. Pharmacotherapy, 2013, 33, 1256-1263.	2.6	53
89	Comparative Incidence of Nephrotoxicity by Age Group among Adult Patients Receiving Vancomycin. Infectious Diseases and Therapy, 2013, 2, 201-208.	4.0	20
90	Early Use of Daptomycin Versus Vancomycin for Methicillin-Resistant Staphylococcus aureus Bacteremia With Vancomycin Minimum Inhibitory Concentration >1 mg/L: A Matched Cohort Study. Clinical Infectious Diseases, 2013, 56, 1562-1569.	5.8	163

#	ARTICLE	IF	CITATIONS
91	Multicenter Study of High-Dose Daptomycin for Treatment of Enterococcal Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 4190-4196.	3.2	80
92	Clinical Outcomes in Patients with Heterogeneous Vancomycin-Intermediate <i>Staphylococcus aureus</i> Bloodstream Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 4252-4259.	3.2	68
93	A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2921-2926.	3.0	90
94	Impact of Vancomycin Exposure on Outcomes in Patients With Methicillin-Resistant <i>Staphylococcus aureus</i> Bacteremia: Support for Consensus Guidelines Suggested Targets. <i>Clinical Infectious Diseases</i> , 2011, 52, 975-981.	5.8	411
95	Nontraditional pharmacy residency at a large teaching hospital. <i>American Journal of Health-System Pharmacy</i> , 2010, 67, 366-370.	1.0	12
96	Implementation of a care bundle for antimicrobial stewardship. <i>American Journal of Health-System Pharmacy</i> , 2010, 67, 746-749.	1.0	51
97	Comparative evaluation of epidemiology and outcomes of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) USA300 infections causing community- and healthcare-associated infections. <i>International Journal of Antimicrobial Agents</i> , 2009, 34, 148-155.	2.5	52
98	Molecular Epidemiology of Methicillin-Resistant <i>Staphylococcus aureus</i> Bloodstream Isolates in Urban Detroit. <i>Journal of Clinical Microbiology</i> , 2008, 46, 2345-2352.	3.9	78
99	Anidulafungin: an evidence-based review of its use in invasive fungal infections. <i>Core Evidence</i> , 2008, 2, 241-9.	4.7	3
100	Epidemiology, Risk Factors, and Outcomes of <i>Candida albicans</i> Versus Non- <i>albicans</i> Candidemia in Nonneutropenic Patients. <i>Annals of Pharmacotherapy</i> , 2007, 41, 568-573.	1.9	90
101	Daptomycin versus Vancomycin for Complicated Skin and Skin Structure Infections: Clinical and Economic Outcomes. <i>Pharmacotherapy</i> , 2007, 27, 1611-1618.	2.6	75
102	Characteristics of Patients With Healthcare-Associated Infection Due to SCCmecType IV Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>Infection Control and Hospital Epidemiology</i> , 2006, 27, 1025-1031.	1.8	100
103	Title is missing!. <i>Journal of Pediatrics</i> , 1995, 126, 678-679.	1.8	2
104	Evaluating the impact of severe sepsis 3-hour bundle compliance on 28-day in-hospital mortality: A propensity adjusted, nested case-control study. <i>Pharmacotherapy</i> , 0, , .	2.6	0